Back to top
more

BioNTech (BNTX)

(Delayed Data from NSDQ)

$291.94 USD

291.94
3,960,171

-10.75 (-3.55%)

Updated Dec 8, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.42%
2Buy19.05%
3Hold10.68%
4Sell6.41%
5Strong Sell3.08%
S&P50011.42%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (154 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Balance Sheet

Research for BNTX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for BioNTech SE Sponsored ADR falls in the month of December.

All items in Millions except Per Share data.

12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Assets          
Cash & Equivalents 1,539 583 486 NA NA
Receivables 190 14 23 NA NA
Notes Receivable 0 0 0 NA NA
Inventories 73 13 7 NA NA
Other Current Assets 102 17 14 NA NA
Total Current Assets 1,904 627 530 NA NA
Net Property & Equipment 259 104 137 NA NA
Investments & Advances 0 0 0 NA NA
Other Non-Current Assets 0 0 0 NA NA
Deferred Charges 184 0 0 NA NA
Intangibles 187 100 104 NA NA
Deposits & Other Assets 1 0 0 NA NA
Total Assets 2,649 893 771 NA NA
Liabilities & Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Notes Payable 0 0 0 NA NA
Accounts Payable 117 23 49 NA NA
Current Portion Long-Term Debt 10 2 0 NA NA
Current Portion Capital Leases 0 0 0 NA NA
Accrued Expenses 0 0 0 NA NA
Income Taxes Payable 0 0 0 NA NA
Other Current Liabilities 565 130 100 NA NA
Total Current Liabilities 692 155 149 NA NA
Mortgages 0 0 0 NA NA
Deferred Taxes/Income 0 0 0 NA NA
Convertible Debt 0 0 0 NA NA
Long-Term Debt 264 0 0 NA NA
Non-Current Capital Leases 0 0 0 NA NA
Other Non-Current Liabilities 125 186 307 NA NA
Minority Interest (Liabilities) 0 0 0 NA NA
Total Liabilities 1,082 341 456 NA NA
Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Preferred Stock 0 0 0 NA NA
Common Stock (Par) 281 260 228 NA NA
Capital Surplus -468 -476 -290 NA NA
Retained Earnings 0 0 0 NA NA
Other Equity 1,759 775 377 NA NA
Treasury Stock 5 6 0 NA NA
Total Shareholder's Equity 1,567 553 315 NA NA
Total Liabilities & Shareholder's Equity 2,649 893 771 NA NA
Total Common Equity 1,567 553 315 0 0
Shares Outstanding 226.20 226.20 NA NA NA
Book Value Per Share 6.93 2.44 0.00 0.00 0.00

Fiscal Year End for BioNTech SE Sponsored ADR falls in the month of December.

All items in Millions except Per Share data.

9/30/2021 6/30/2021 3/31/2021 12/31/2020 9/30/2020
Assets          
Cash & Equivalents 2,824 1,102 1,075 1,539 1,179
Receivables 12,505 8,498 2,889 190 9
Notes Receivable 0 0 0 0 0
Inventories 464 368 177 73 14
Other Current Assets 187 201 122 102 74
Total Current Assets 15,980 10,169 4,263 1,904 1,276
Net Property & Equipment 347 315 292 259 149
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 89 197 171 184 0
Intangibles 192 198 199 187 197
Deposits & Other Assets 1 1 1 1 6
Total Assets 16,783 11,023 5,069 2,649 1,694
Liabilities & Shareholders Equity 9/30/2021 6/30/2021 3/31/2021 12/31/2020 9/30/2020
Notes Payable 0 0 0 0 0
Accounts Payable 305 317 128 117 49
Current Portion Long-Term Debt 22 17 22 10 4
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 3,677 0 0 0 0
Other Current Liabilities 1,776 3,478 1,431 565 261
Total Current Liabilities 5,781 3,811 1,581 692 314
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 316 293 285 264 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 414 166 125 296
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 6,510 4,417 2,032 1,082 610
Shareholders Equity 9/30/2021 6/30/2021 3/31/2021 12/31/2020 9/30/2020
Preferred Stock 0 0 0 0 0
Common Stock (Par) 290 297 297 281 288
Capital Surplus 0 4,224 866 -468 -908
Retained Earnings 7,920 0 0 0 0
Other Equity 2,066 2,090 1,880 1,759 1,711
Treasury Stock 4 5 6 5 6
Total Shareholder's Equity 10,273 6,606 3,038 1,567 1,084
Total Liabilities & Shareholder's Equity 16,783 11,023 5,069 2,649 1,694
Total Common Equity 10,273 6,606 3,038 1,567 1,084
Shares Outstanding 242.50 241.50 241.50 226.20 226.20
Book Value Per Share 42.36 27.35 12.58 6.93 4.79